Search
for
Sort by
Research 91–120 of 121
- Dutasteride
- Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
- Clinical review of ejaculatory dysfunction
- Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
- Prevention of unfavourable effects of cigarette smoke on flap viability using botulinum toxin in random pattern flaps: An experimental study
- Economic Issues in the Treatment of BPH
- Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
- Treatment Response to Conventional and Novel Therapies in Chronic Prostatitis
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- The association of medications and supplements with human male reproductive health: a systematic review
- Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments
- High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Beeinflussen Medikamente gegen das benigne Prostatasyndrom Stimmung oder Kognition?
- 5ARIs and PSA: Evidences
- Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
- The adverse effects of commonly used medications on male fertility: a comprehensive review
- 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Efficacy and safety of α-blockers plus 5α-reductase inhibitors for benign prostatic hyperplasia: a systematic review and meta-analysis
- SRD5A2 and emerging therapies in androgen-driven disorders
- Differential association between cumulative dose of 5α-reductase inhibitors and mortality
- Intraoperative Iris Behavior during Phacoemulsification Maneuvers in Rabbits Treated with Selective α1-Blocker, 5α-Reductase Inhibitor, or Anxiolytic Medication
- Bioprospecting of Potential Inhibitors of 5alpha Reductase 2 Inhibitors from Relevant Ethno-pharmacological Plants via In Silico Techniques
- ZALCITABINE
- Treatment response to conventional and novel therapies in chronic prostatitis
- Dihydrotestosterone and 5α-Reductase
- Floppy Iris Syndrome
- Safety and Efficacy of the Coadministration of Sildenafil and Finasteride
- Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia